Allied Biotech Corporation (TPEX:1780)
Taiwan
· Delayed Price · Currency is TWD 30.80
-0.25 (-0.81%)
Apr 29, 2026, 1:07 PM CST
Allied Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 129.46 | 100.94 | 97.41 | 146.74 | 13.04 | Upgrade
|
| Depreciation & Amortization | 61 | 61.94 | 69.45 | 71.76 | 65.24 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.86 | - | - | 1.59 | - | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | - | 2 | - | Upgrade
|
| Other Operating Activities | 4.16 | -2.7 | -16.62 | 31.82 | -9.13 | Upgrade
|
| Change in Accounts Receivable | -6.7 | -21.69 | 8.62 | -16.2 | 13.7 | Upgrade
|
| Change in Inventory | 16.13 | 73.94 | -5 | -88.39 | -22.84 | Upgrade
|
| Change in Accounts Payable | 3.9 | -1.4 | -10.69 | -0.41 | 10.7 | Upgrade
|
| Change in Unearned Revenue | -0.91 | -2.04 | 3.39 | -0.34 | 0.88 | Upgrade
|
| Change in Other Net Operating Assets | 9.25 | 14.8 | -8.95 | 15.7 | 0.83 | Upgrade
|
| Operating Cash Flow | 217.13 | 223.79 | 137.62 | 164.27 | 72.43 | Upgrade
|
| Operating Cash Flow Growth | -2.98% | 62.62% | -16.23% | 126.81% | 21.77% | Upgrade
|
| Capital Expenditures | -89.51 | -26.81 | -47.91 | -54.66 | -49.99 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.11 | - | Upgrade
|
| Investment in Securities | - | 97.37 | 6.98 | 273.57 | -130.95 | Upgrade
|
| Other Investing Activities | 0.02 | -0.02 | -0.01 | - | - | Upgrade
|
| Investing Cash Flow | -89.49 | 70.55 | -40.94 | 219.02 | -180.94 | Upgrade
|
| Short-Term Debt Issued | - | 170 | - | - | 265 | Upgrade
|
| Long-Term Debt Issued | - | 58.87 | - | 107.68 | - | Upgrade
|
| Total Debt Issued | - | 228.87 | - | 107.68 | 265 | Upgrade
|
| Short-Term Debt Repaid | -200 | - | -20 | -390 | - | Upgrade
|
| Long-Term Debt Repaid | -24.04 | -82.99 | -24.17 | -132.32 | -24.76 | Upgrade
|
| Total Debt Repaid | -224.04 | -82.99 | -44.17 | -522.32 | -24.76 | Upgrade
|
| Net Debt Issued (Repaid) | -224.04 | 145.88 | -44.17 | -414.64 | 240.24 | Upgrade
|
| Common Dividends Paid | -96.02 | -81.42 | -114.46 | -47.68 | -76.12 | Upgrade
|
| Other Financing Activities | 0.73 | 0.48 | 0.3 | 0.32 | 0.12 | Upgrade
|
| Financing Cash Flow | -319.33 | 64.94 | -158.33 | -462 | 164.24 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.44 | 0.56 | 0.39 | 1.07 | -1.82 | Upgrade
|
| Net Cash Flow | -189.25 | 359.84 | -61.26 | -77.64 | 53.91 | Upgrade
|
| Free Cash Flow | 127.62 | 196.98 | 89.71 | 109.62 | 22.44 | Upgrade
|
| Free Cash Flow Growth | -35.21% | 119.58% | -18.16% | 388.49% | 744.88% | Upgrade
|
| Free Cash Flow Margin | 15.02% | 24.41% | 12.45% | 15.29% | 3.32% | Upgrade
|
| Free Cash Flow Per Share | 1.32 | 2.04 | 0.94 | 1.14 | 0.23 | Upgrade
|
| Cash Interest Paid | 17.33 | 13.58 | 12.87 | 11.65 | 11.06 | Upgrade
|
| Cash Income Tax Paid | 30.73 | 32.55 | 40.65 | 5.66 | 13.88 | Upgrade
|
| Levered Free Cash Flow | 48.27 | 135.02 | 33.04 | 17.52 | 65.85 | Upgrade
|
| Unlevered Free Cash Flow | 59.1 | 143.74 | 41.13 | 24.86 | 72.88 | Upgrade
|
| Change in Working Capital | 21.67 | 63.61 | -12.63 | -89.63 | 3.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.